Craig Gibbs, PhD, MBA has been Chief Executive Officer of Asher Biotherapeutics Inc. since September of 2020 and also serves on the Boards of Directors of Aridis Pharmaceuticals Inc. and Inipharm Inc. and the Board of Trustees for the Leukemia and Lymphoma Society. From September 2015 until April 2020, Dr. Gibbs was the Chief Business Officer at Forty Seven Inc. and served on the Board of Directors of Tobira Therapeutics from May 2013 to September 2016. From 1992 to 2013, Dr. Gibbs worked for Gilead Sciences in a variety of leadership positions spanning Biology Research, Corporate Development and, most recently, Vice President of Commercial Strategy/Commercial Planning and Operations. Prior to Gilead, Dr. Gibbs served as a Scientist in the Department of Protein Engineering at Genentech, Inc. He received his BSc in Biochemistry from Massey University and his PhD in Molecular Biology from the University of Glasgow in Scotland and his MBA from Golden Gate University.